which is a continuation of 08/469,773, filed June 6, 1995, abandoned, which is a continuation of 08/150,011, filed January 13, 1994, abandoned, which was the national phase of PCT/FR93/00264, filed March 16,1993 as WO/9319191.

In the Claims

Please cancel claims ~~19~~ to 22 without prejudice or disclaimer of the subject matter contained therein.

Please amend the following claims:

15. (Once Amended) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition into said tumor wherein said pharmaceutical composition comprises:

(a) an adenoviral vector wherein said adenoviral vector:

(i) is replication-defective and lacks the E1A, E1B and E3 regions of said adenovirus; and

(ii) comprises a nucleic acid sequence coding for a cytokine, under the control of an endogenous or heterologous promoter; and wherein said cytokine is interleukin-2 or gamma-interferon; and

(b) a pharmaceutically acceptable vehicle.

16. (Once Amended) The method according to Claim 15, wherein said adenoviral vector retains the early promoter of the E1A region of the adenovirus, and wherein the nucleic acid sequence coding for the cytokine is under the control of said early E1A promoter.

17. (Once Amended) The method according to Claim 15, wherein said nucleic acid sequence coding for said cytokine is under the control of an adenovirus late promoter.

18. (Once Amended) The method according to Claim 15, wherein said nucleic acid sequence coding for said cytokine is under the control of said heterologous promoter.

Please add the following new claims 23-25:

23. (New) The method according to Claim 18, wherein said heterologous promoter is the promoter of the IE gene of cytomegalovirus.

24. (New) A method for treating a tumor in a patient in need of such treatment, said method comprising injecting an effective amount of a pharmaceutical composition wherein said pharmaceutical composition comprises:

(a) an adenoviral vector wherein said adenoviral vector:

(i) is replication-defective and lacks the E1A, E1B and E3 regions of said adenovirus; and

(ii) comprises a nucleic acid sequence coding for a cytokine, under the control of an endogenous or heterologous promoter; and wherein said cytokine is GM-CSF, and

(b) a pharmaceutically acceptable vehicle.

25. (New) The method according to Claim 24, wherein said adenoviral vector further comprises a nucleic acid sequence coding for an interleukin-2 under the control of an

endogenous or heterologous promoter and wherein said interleukin-2 under the control of said endogenous or heterologous promoter is placed after said nucleic acid sequence coding for a cytokine in said adenoviral vector.